SILK - Silk Road Medical falls after Citigroup downgrades to Sell from Neutral
- Citigroup downgraded medical device company Silk Road Medical ( NASDAQ: SILK ) to Sell from Neutral in a research note issued on Monday.
- The firm has a price target of $33, implying a downside risk of ~22% from stock's last close.
- Shares of SILK are down 4.8% to trade at $40.15 on Monday vs. a 52-week trading range of $27.21 to $67.49
- Seeking Alpha Quant Rating systems give a Hold while Wall Street analysts maintain a Buy rating on the stock.
For further details see:
Silk Road Medical falls after Citigroup downgrades to Sell from Neutral